The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients
Open accessAbstract
Prediction of survival for patients with metastatic breast cancer is often inaccurate and may be helped by new biological parameters. Tumour growth being angiogenesis-dependent, it has been hypothesised that the assessment of angiogenic factor production might reflect the clinical behaviour of cancer progression. This study was designed to investigate the clinical significance of vascular endothelial growth factor (VEGF) and interleukin 6 (IL-6) in hormone-refractory metastatic breast cancer. Serum and plasma concentrations of VEGF and serum concentration of IL-6 were measured in 87 patients with a fully documented history of metastatic breast cancer using an enzyme-linked immunoassay. All patients had detectable levels of VEGF, whereas 39% patients had detectable serum levels of IL-6. There was a positive correlation between IL-6 levels and the theoretical VEGF load of platelets (P<0.001). The presence of high levels of serum IL-6, but not VEGF, was significantly correlated to a shorter survival. In a multivariate analysis along with clinical prognostic parameters, serum IL-6 was identified as an independent adverse prognostic variable for overall survival (P&<0.001). These results indicate that serum IL-6 levels correlate to poor survival in patients with hormone-refractory metastatic breast cancer. Vascular endothelial growth factor serum and plasma levels are not useful indicators of prognosis for these patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885
Interleukin-6 family of cytokines and gp130
Kishimoto, T., Akira, S., Narazaki, M., & Taga, T. (1995) · Blood · doi:10.1182/blood.v86.4.1243.bloodjournal8641243 · Cited by 1,272
Interleukin 6 Induces the Expression of Vascular Endothelial Growth Factor
Cohen, T., Nahari, D., Cerem, L. W., Neufeld, G., & Levi, B.-Z. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.2.736 · Cited by 1,039
Banks, R., Forbes, M., Kinsey, S., Stanley, A., Ingham, E., Walters, C., & Selby, P. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.158 · Cited by 599
Menetrier-Caux, C., Montmain, G., Dieu, M. C., Bain, C., Favrot, M. C., Caux, C., & Blay, J. Y. (1998) · Blood · doi:10.1182/blood.v92.12.4778 · Cited by 590
Self-citationClinical Implications of Circulating Angiogenic Factors in Cancer Patients
Poon, R. T.-P., Fan, S.-T., & Wong, J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.4.1207 · Cited by 587
Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma.
Blay, J., Négrier, S., Combaret, V., Attali, S., Goillot, E., Merrouche, Y., Mercatello, A., Ravault, A., Tourani, J. M., & Jf, M. (1992) · PubMed · Cited by 420
Self-citationUgurel, S., Rappl, G., Tilgen, W., & Reinhold, U. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.2.577 · Cited by 399
Kraft, A., Weindel, K., Ochs, A., Marth, C., Zmija, J., Schumacher, P., Unger, C., Marm�, D., & Gastl, G. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990101)85:1<178::aid-cncr25>3.0.co;2-7 · Cited by 372
Serum interleukin 6 as a prognostic factor in patients with prostate cancer.
Nakashima, J., Tachibana, M., Horiguchi, Y., Oya, M., Ohigashi, T., Asakura, H., & Murai, M. (2000) · PubMed · Cited by 351
Adams, J., Carder, P. J., Downey, S. E., Forbes, M. A., MacLennan, K. A., Allgar, V. L., Kaufman, S., Hallam, S., Bicknell, R., Walker, J. J., et al. (2000) · PubMed · Cited by 339
Prognostic Value of Vascular Endothelial Growth Factor in Breast Cancer
Gasparini, G. (2000) · The Oncologist · doi:10.1634/theoncologist.5-2004-37 · Cited by 322
Zhang, G.-J., & Adachi, I. (1999) · PubMed · Cited by 306
Dirix, L., Vermeulen, P., Pawinski, A., Prové, A., Benoy, I., De Pooter, C., Martin, M., & Van Oosterom, A. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.368 · Cited by 272
Blay, J.-Y., Rossi, J.-F., Wijdenes, J., Menetrier-Caux, C., Schemann, S., Négrier, S., Philip, T., & Favrot, M. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970729)72:3<424::aid-ijc9>3.0.co;2-r · Cited by 261
Self-citationSalvén, P., Orpana, A., & Joensuu, H. (1999) · PubMed · Cited by 252
Salven, P., Orpana, A., Teerenhovi, L., & Joensuu, H. (2000) · Blood · doi:10.1182/blood.v96.12.3712 · Cited by 234
George, M. L., Eccles, S. A., Tutton, M. G., Abulafi, A. M., & Swift, R. I. (2000) · PubMed · Cited by 233
Lu, C., & Kerbel, R. S. (1993) · The Journal of cell biology · doi:10.1083/jcb.120.5.1281 · Cited by 224
Badache, A., & Hynes, N. E. (2001) · PubMed · Cited by 219
Yoshiji, H., Harris, S. R., & Thorgeirsson, U. P. (1997) · PubMed · Cited by 206
Salgado, R., Vermeulen, P. B., Benoy, I., Weytjens, R., Huget, P., Marck, E. V., & Dirix, L. Y. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690437 · Cited by 165
and the Danish RANX05 Colorectal Cancer Study Group, Werther, K., Christensen, I. J., & Nielsen, H. J. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600075 · Cited by 123
Serum VEGF levels in women with a benign breast tumor or breast cancer
Salvén, P., Perhoniemi, V. J., Tykkä, H., Mäenpää, H. O., & Joensuu, H. (1999) · Breast Cancer Research and Treatment · doi:10.1023/a:1006178517505 · Cited by 114
Wynendaele, W., Derua, R., Hoylaerts, M., Pawinski, A., Waelkens, E., de Bruijn, E. A., Paridaens, R., Merlevede, W. J., & van Oosterom, A. T. (1999) · Annals of Oncology · doi:10.1023/a:1008377921886 · Cited by 110
Degeorges, A., Tatoud, R., Fauvel-Lafève, F., Podgorniak, M.-P., Millot, G., de Crémoux, P., & Calvo, F. M. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19961009)68:2<207::aid-ijc12>3.0.co;2-7 · Cited by 102
Interleukin 6 acts as a paracrine growth factor in human mammary carcinoma cell lines.
Chiu, J., Sgagias, M. K., & Cowan, K. H. (1996) · PubMed · Cited by 99
Manders, P., Beex, L. V. A. M., Tjan‐Heijnen, V. C. G., Geurts-Moespot, J., van Tienoven, T., Foekens, J. A., & Sweep, F. C. G. J. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600555 · Cited by 90
Singh, A., Purohit, A., Ghilchik, M., & Reed, M. J. (1999) · Endocrine-Related Cancer · doi:10.1677/erc.0.0060139 · Cited by 84
Nuclear Factor Interleukin 6 Motifs Mediate Tissue-specific Gene Transcription in Hypoxia
Yan, S., Zou, Y. S., Mendelsohn, M. M., Gao, Y. J., Naka, Y., Yan, S. D., Pinsky, D. J., & Stern, D. M. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.7.4287 · Cited by 77
Duncan, L., Coldham, N. G., & Reed, M. J. (1994) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(94)90301-8 · Cited by 64
Arterio-venous gradients of IL-6, plasma and serum VEGF and D-dimers in human cancer
Salgado, R., Benoy, I. H., Weytjens, R., Bockstaele, D. R. V., Marck, E. V., Huget, P., Hoylaerts, M., Vermeulen, P., & Dirix, L. Y. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600655 · Cited by 57
Expression of interleukin 6 (IL-6) correlates with oestrogen receptor in human breast carcinoma
Fontanini, G., Campani, D., Roncella, M., Cecchetti, D., Calvo, S., Toniolo, A., & Basolo, F. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690394 · Cited by 55
Grano, M., Mori, G., Minielli, V., Cantatore, F. P., Colucci, S., & Zallone, A. Z. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.2569 · Cited by 54
Duletić‐Načinović, A., Gačić, V., Valković, T., Lučin, K., Fišić, E., Žuvić-Butorac, M., Seili‐Bekafigo, I., & Jonjić, N. (2016) · Acta Haematologica · doi:10.1159/000444624 · Cited by 46
Speirs, V., Kerin, M. J., Walton, D. S., NEWTON, C. J., Desai, S. B., & Atkin, S. L. (2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.1097 · Cited by 35
Cytokine suppression of protease activation in wild-type p53-dependent and p53-independent apoptosis
Lotem, J., & Sachs, L. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.17.9349 · Cited by 33
Long term survivors of childhood brain cancer have an increased risk for cardiovascular disease
(2000) · Pure Amsterdam UMC · doi:10.1002/(sici)1097-0142(20000501)88:9
Cited by
Obesity and Cancer Mechanisms: Tumor Microenvironment and Inflammation
Iyengar, N. M., Gucalp, A., Dannenberg, A. J., & Hudis, C. A. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.4283 · Cited by 1,004
Sansone, P., Storci, G., Tavolari, S., Guarnieri, T., Giovannini, C., Taffurelli, M., Ceccarelli, C., Santini, D., Paterini, P., Marcu, K. B., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32533 · Cited by 779
Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells
Sullivan, N. J., Sasser, A. K., Axel, A. E., Vesuna, F., Raman, V, Ramirez, N., Oberyszyn, T. M., & Hall, B. M. (2009) · Oncogene · doi:10.1038/onc.2009.180 · Cited by 757
Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling
Jones, S. A., Scheller, J., & Rose-John, S. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57158 · Cited by 683
Korkaya, H., Kim, G.-I., Davis, A., Malik, F., Henry, N. L., Ithimakin, S., Quraishi, A. A., Tawakkol, N., D'Angelo, R., Paulson, A. K., et al. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.06.014 · Cited by 538
Metadata
- Authors
- Bachelot, T., Ray-Coquard, I., Menetrier-Caux, C., Rastkha, M., Duc, A., & Blay, J.-Y.
- Venue
- British Journal of Cancer
- Published
- 2003-05-27
- Volume
- 88
- Issue
- 11
- Pages
- 1721-1726
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2079989335
- Cited by
- 317
- References
- 38
- FWCI
- 3.12
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.